Impact of SARS-CoV-2 infection on longitudinal vaccine immune responses

- 3 Sebastian Havervall, MD<sup>1</sup>, Ulrika Marking, MD<sup>1</sup>, Nina Greilert-Norin, RN<sup>1</sup>, Max
- 4 Gordon, MD, PhD<sup>1</sup>, Henry Ng, MMSc<sup>1,2</sup>, Wanda Christ, MMSc<sup>3</sup>, Kim Blom, PhD<sup>1,4</sup>,
- 5 Mia Phillipson, PhD<sup>2</sup>, Peter Nilsson, PhD<sup>5</sup>, Sophia Hober, PhD<sup>5</sup>, Jonas Klingström,
- 6 PhD <sup>3,4</sup>, Sara Mangsbo, PhD<sup>6</sup>, Mikael Åberg<sup>#</sup>, PhD<sup>7</sup>, and Charlotte Thålin<sup>#</sup>, MD, PhD<sup>1</sup>
- 9 1. Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital,
- 10 Stockholm, Sweden
- 2. Department of Medical Cell Biology and SciLifeLab, Uppsala University, Uppsala,
- 12 Sweden

1

2

7 8

21

2324

- 13 3. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska
- 14 Institutet, Stockholm, Sweden
- 4. Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden
- 16 5. Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab,
- 17 Stockholm, Sweden
- 18 6. Department of Pharmacy and SciLifeLab, Uppsala University, Uppsala, Sweden
- 19 7. Department of Medical Sciences, Clinical Chemistry and SciLifeLab, Uppsala
- 20 University, Uppsala, Sweden
- 22 # These authors contributed equally
- 25 Corresponding author:
- 26 Charlotte Thålin, MD, PhD
- 27 Department of Clinical Sciences
- 28 Karolinska Insitutet
- 29 18288 Danderyd Hospital
- 30 Sweden
- 31 Phone: +46 8123 55000
- 32 Mail: charlotte.thalin@ki.se

35 Abstract 36 Background 37 Recent serological investigations imply waning immune responses following SARS-38 CoV-2 vaccination, but prior infection may impact the breadth and duration of vaccine 39 immune responses. 40 41 Methods 42 Using longitudinally collected blood samples from the COMMUNITY study, we 43 determined binding (WHO BAU/ml) and neutralizing antibody titers against ten 44 SARS-CoV-2 variants over seven months following BNT162b2 in healthcare workers 45 with (n=111) and without (n=298) confirmed prior SARS-CoV-2 infection. A smaller 46 group with (n=47) and without (n=61) confirmed prior SARS-CoV-2 infection 47 receiving ChAdOx1 nCoV-19 was followed for three months. 48 49 Results 50 Vaccination (BNT162b2 and ChAdOx1 nCoV-19) following SARS-CoV-2 infection 51 resulted in higher wild-type BAU/ml geometric mean titers (GMTs) at all sampling 52 time points when compared to SARS-CoV-2 naïve vaccinees (all p<0.001). GMTs 53 were 1875 BAU/ml in convalescent and 981 BAU/ml in naïve BNT162b2 vaccinees 6 54 weeks post vaccination. 29 weeks post vaccination, GMTs had decreased to 524 55 BAU/ml in convalescent and 148 BAU/ml in naïve vaccinees. GMT differences 56 between convalescents and naïve following ChAdOx1 nCoV-19 mirrored those after 57 BNT162b2, but the titers were 4.5-fold lower following ChAdOx1 ncov-19 as 58 compared to those after BNT162b2 (p<0.001). Finally, at all time points, neutralizing 59 antibody titers against all ten tested SARS-CoV-2 variants were at least 2 60 respectively 3-fold higher in SARS-CoV-2 recovered as compared to naïve vaccinees 61 following BNT162b2 and ChAdOx1 nCoV-19, respectively (all p<0.001). 62 63 **Conclusions** 64 These findings of substantially more robust serological responses to vaccine after 65 natural infection imply that prior infection may be taken into consideration when 66 planning booster doses and design of current and future SARS-CoV-2 vaccine 67 programs.

Introduction 68 69 Clinical trials and post marketing effectiveness data have shown that currently used 70 COVID-19 vaccines protect strongly against hospitalization and death in most 71 settings <sup>1-3</sup>. However, real-world efficacy estimates are affected by population 72 demographics, characteristics of circulating SARS-CoV-2 variants, vaccine protocols 73 and time since vaccination. An increased risk of breakthrough infections is now observed, partly explained by immune waning 4-8. A robust immune response after 74 infection or vaccination is based on the induction of memory B and T cells generating 75 virus specific antibodies and T-cell responses 9-13. Antibody levels have been shown 76 to correlate inversely with risk of SARS-CoV-2 infection <sup>14,15</sup> and may, with 77 standardized readouts <sup>16</sup>, be used as a marker for correlates of protection. Time 78 between prime and boost <sup>17</sup>, the number of boosters administrated as well as 79 infection prior to vaccination <sup>18</sup> impact the breadth and duration of immune 80 81 responses. As an increasing number of persons become infected globally, 82 vaccination post SARS-CoV-2 infection will become more frequent. Prior SARS-CoV-2 infection has been reported to positively impact vaccine responses <sup>9,19-24</sup> but little is 83 84 known regarding long term effects. Although available vaccines have been proven safe and efficacious, they are not free of unforeseen adverse events <sup>25,26</sup>. To 85 86 optimize immunization programs, it is therefore crucial to study duration of immune 87 responses including direct comparisons of vaccine platforms and the long-term effect 88 of prior SARS-CoV-2 infection on subsequent vaccine-induced responses in real 89 world evidence studies. 90 Using longitudinally collected blood samples from the COMMUNITY (COVID-19 91 Immunity) study <sup>13,24,27,28</sup> we herein report binding and pseudo-neutralizing antibody 92 93 titers elicited over seven months following mRNA BNT162b2 (Comirnaty, Pfizer 94 BioNTech) and over three months following adenovirus-vectored ChAdOx1 nCoV-19 95 (Vaxzevria, AstraZeneca) vaccination in 517 healthcare workers (HCW) with and 96 without confirmed SARS-CoV-2 infection prior to vaccination. 97 98 Methods 99 Study population 100 The COMMUNITY study enrolled 2149 HCW at Danderyd Hospital, Stockholm, 101 Sweden, in April and May 2020. SARS-CoV-2 spike-specific IgG are analyzed every

104

105

106107

108109

110

111

112113

114

115

116

117118

119

120

121122

123

124

125

126127

128

129

130131132

133

134135

four months by multiplex antigen bead array <sup>29</sup>. All HCW at Danderyd Hospital were offered vaccination with either BNT162b2 or ChAdOx1 nCoV-19, depending on availability, starting January 2021. Date and type of vaccine was obtained through the Swedish vaccination register (VAL Vaccinera). This sub-study included a total of 517 HCW stratified into two groups depending on SARS-CoV-2 infection prior to vaccination. Previous SARS-CoV-2 infection was confirmed by SARS-CoV-2 spike-specific IgG seroconversion at any of the fourmonth follow-ups since study inclusion in April 2020. 337 HCW received BNT162b2 with a 3-week dose interval (range 21-28 days) between January 12<sup>th</sup> and February 24<sup>th</sup>, 2021. These were sampled at 6 weeks (range 5-8 weeks; 69 SARS-CoV-2 naïve and 27 SARS-CoV-2 recovered vaccinees)). 12 weeks (range 11-14 weeks: 175 SARS-CoV-2 naïve and 52 SARS-CoV-2 recovered) and 29 weeks (range 27-30 weeks; 246 SARS-CoV-2 naïve vaccinees and 68 SARS-CoV-2 recovered) post second BNT162b2 dose, respectively. 72 HCW received BNT162b2 with a 6-week dose interval (range 39-52 days) between April 17th and July 2nd, 2021 and were sampled at 12 weeks (range 11-14 weeks; 36 SARS-CoV-2 naïve and 36 SARS-CoV-2 recovered) post second BNT162b2 dose. ChAdOx1 nCoV-19 vaccinees were fully vaccinated at a later time point than BNT162b2 vaccinees, between February 25<sup>th</sup> and May 31<sup>st</sup>, 2021. 108 HCW received ChAdOx1 nCoV-19 with a 12-week dose interval (range 71-92 days) and were sampled at 3 weeks (range 2-3 weeks; 48 SARS-CoV-2 naïve and 35 SARS-CoV-2 recovered) and 14 weeks (range 13-15 weeks: 56 SARS-CoV-2 naïve and 44 SARS-CoV-2 recovered) post second dose. respectively. Figure 1. Demographics and vaccine status of the study population are presented in Table 1. The study is approved by the Swedish Ethical Review Authority (dnr 2020-01653) and written informed consent was obtained from all study participants. Binding and pseudo-neutralizing antibodies Binding antibodies (IgG) and pseudo-neutralizing antibodies against SARS-CoV-2 wild type (WT) and B.1.1.7 (Alpha), B.1.351 (Beta), B.1.526.1 (New York), B.1.617 (India), B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3 (India), P.1 (Gamma), and

136 P.2 (Zeta) variants, were measured in post vaccination samples using the V-PLEX SARS-CoV-2 Panel 13 (Meso Scale Diagnostics, USA) for IgG and ACE2 137 138 (quantifying the ability to inhibit the binding between the ACE2 receptor and the spike 139 protein), respectively. Binding antibody titers for WT were calibrated against the WHO standard<sup>16</sup> according to the manufacturer's instructions and presented as 140 Binding Antibody Units (BAU)/ml. Pseudo-neutralizing antibodies are expressed as 141 142 arbitrary units (AU)/ml. 143 144 Microneutralization assay 145 Microneutralization based on cytopathic effects (CPE) was performed essentially as previously described <sup>30</sup>. Briefly, serum was 3-fold serially diluted, mixed with virus, 146 147 incubated for 1 hour and finally added, in duplicates, to confluent Vero E6 cells in 96-148 well plates. Original SARS-CoV-2 WT (isolated from a Swedish patient) and the Delta 149 variant (from Statens Serum Institut, Copenhagen, Denmark), were used. After 5 150 days incubation, the wells were inspected for signs of CPE by optical microscopy. 151 Each well was scored as either neutralizing (if no signs of CPE was observed) or 152 non-neutralizing (if any CPE was observed). The arithmetic mean neutralization titer 153 of the reciprocals of the highest neutralizing dilutions from the two duplicates for each 154 sample was then calculated. 155 156 Statistical analyses 157 Spike IgG and pseudo-neutralizing antibody titers are presented as geometric mean 158 titers (GMTs) with 95% confidence interval (CI). Linear regression was used to 159 compare continuous variables between groups and were adjusted for sex and age. 160 Multiple samples per subject were analyzed using linear mixed effects regression 161 with random intercepts per subject using the same adjustments as for linear 162 regression. The correlation coefficient was calculated using Spearman's correlation 163 analysis. Linear regression and mixed effects regressions were performed in R 164 (version 4.1.1) with nlme-package version 3.1.152 and contrast-package 0.22 while 165 the remainder were done in GraphPad Prism (version 9.1.1). 166 167 Results Antibody responses over seven months following BNT162b2 vaccination in 168 169 SARS-CoV-2 recovered and naïve individuals

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196 197

198

199

200201

202

Almost all (99.8%) participants had detectable levels of spike IgG antibodies after vaccination. Notably, at all sampling time points, spike IgG GMTs were markedly higher in previously SARS-CoV-2 infected vaccinees compared to SARS-CoV-2 naïve vaccinees (all p<0.001). Table 2 and Figure 2A. A decrease of spike IgG GMTs by 2-fold between week 6 and 12, and by 6.6-fold between week 6 and 29 were observed in SARS-CoV-2 naïve BNT162b2 vaccinees. This decrease was not as explicit in vaccinees with SARS-CoV-2 infection prior to vaccination, as GMTs decreased by 1.5-fold between week 6 and 12, and by 3.6-fold between week 6 and 29 post vaccination. Binding spike IgG titers correlated strongly to pseudo-neutralizing antibody titers against both the WT and the Delta variant (Spearman's rank correlation coefficient 0.92, and 0.83, respectively, both p<0.0001). Consistent with spike IgG, substantially higher GMTs of pseudo-neutralizing antibodies were observed in vaccinees with SARS-CoV-2 infection prior to vaccination compared to SARS-CoV-2 naïve vaccinees at all sampling time points (all p<0.001). Table 2 and Figure 2B-C. Among SARS-CoV-2 naïve vaccinees, GMTs of pseudo-neutralizing antibodies against the WT and Delta variant decreased by 1.8-fold and 2.6-fold between week 6 and 12, and by 3.3-fold and 4.6-fold between week 6 and 29, respectively. For vaccinees with SARS-CoV-2 infection prior to vaccination, GMTs of pseudo-neutralizing antibodies against the WT and Delta variant decreased by 2.3-fold and 2.1-fold between weeks 6 and 12, and by 5.1-fold and 3.6-fold between weeks 6 and 29, respectively. Table 2 and Figure 2B-C. Notably, pseudo-neutralizing GMTs against the Delta variant reached similar levels and trajectories as pseudo-neutralizing GMTs against the WT, indicating a similar trend in response for the currently circulating Delta variant as for the initially circulating WT. Table 2 and Figure 2B-C. Effect of BNT162b2 dose interval on antibody levels It has been reported that a longer interval between BNT162b2 doses can result in higher antibody titres <sup>31</sup>. In this cohort, BNT162b2 vaccinees were administered with a 3-4 week dose interval in January to February 2021, and with a prolonged dose interval of 6-8 weeks in April to July 2021.

204

205

206

207

208

209

210

211212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235236

12 weeks post second dose, there were no significant differences in spike IgG GMTs following BNT162b2 with the 3-4 week and the 6-8-week dose interval, regardless of prior SARS-CoV-2 infection (all p>0.05). Table 2. Pseudo-neutralizing antibody GMTs against both the WT and Delta variant were, however, slightly but significantly increased 12 weeks following second dose after the prolonged dose interval (p=0.016 and p=0.017, respectively) in SARS-CoV-2 naïve vaccinees when adjusted for sex and age. A similar trend was seen in SARS-CoV-2 recovered vaccinees, although the differences were not significant (all p>0.05). Table 2. Antibody responses over three months following ChAdOx1 nCoV-19 vaccination in SARS-CoV-2 recovered and naïve individuals As data following BNT162b2 vaccination displayed an improved long-term immune response in SARS-CoV-2 recovered individuals we also explored this in the context of the ChAdOx1 nCoV-19 vaccine. Spike IgG GMTs in SARS-CoV-2 naïve vaccinees were 4.5-fold lower following ChAdOx1 nCoV-19 as compared to those after BNT162b2 (p<0.001). Similar to what was observed after BNT162b2 vaccination, spike IgG GMTs were substantially increased in SARS-CoV-2 recovered ChAdOx1 nCoV-19 vaccinees compared to SARS-CoV-2 naïve vaccinees at all sampling time points (all p<0.001). Table 2 and Figure 2A-C. In SARS-CoV-2 naïve vaccinees, spike IqG GMTs declined 1.9-fold between week 3 and 14 post vaccination, whereas GMTs declined 2.3-fold between week 3 and 14 post vaccination in SARS-CoV-2 recovered vaccinees. Consistent with binding antibodies, substantially higher GMTs of pseudo-neutralizing antibodies were observed in SARS-CoV-2 recovered ChAdOx1 nCoV-19 vaccinees compared to SARS-CoV-2 naïve vaccinees at all sampling time points (all p<0.001). Table 2 and Figure 2 B-C. In SARS-CoV-2 naïve vaccinees, GMTs against the WT and Delta variant decreased by 1.4-fold and 3-fold between week 3 and 14, respectively, whereas they decreased by 1.3-fold and 1.5-fold, respectively, in SARS-CoV-2 recovered vaccinees. Similar to findings following BNT162b2 vaccination, GMTs against the Delta variant reached comparable levels and trajectories as GMTs against the WT. Table 2 and Figure 2 B-C.

238

239

240

241

242

243

244

245246

247

248

249

250

251

252

253

254

255

256

257258259

260

261

262

263

264

265

266

267

268

269

Live-microneutralization compared to pseudo-neutralization As a slightly higher capacity to inhibit binding of the Delta variant compared to the WT was found using the pseudo-neutralizing assay (Figure 2B-C), a live-neutralizing assay was performed in a sub-set of 34 (17 SARS-CoV-2 naïve BNT162b2 vaccinees and 17 SARS-CoV-2 naïve ChAdOx1 nCoV-19 vaccinees) participants. While results from these two assays correlated with regard to the WT and the Delta variant (rS=0.66 and 0.63 respectively, both p<0.0001), the live-microneutralization assay resulted in 25.2 % lower titres against the Delta variant compared to the WT. Neutralization capacity against SARS-CoV-2 variants in vaccinees with and without SARS-CoV-2 infection prior to vaccination In light of the substantial increases in antibody titres observed in SARS-CoV-2 recovered vaccinees as compared to SARS-CoV-2 naïve vaccinees, we proceeded to determine if SARS-CoV-2 variants contributed differently. Pseudo-neutralizing antibody titres were assessed against ten SARS-CoV-2 variants, including all variants of concern (VOC) (B.1.1.7 (Alpha), B.135.1 (Beta), P.1 (Gamma) and B.1.617.2 (Delta)). Notably, neutralizing antibody titers against all ten tested SARS-CoV-2 variants were at least 2 respectively 3-fold higher in SARS-CoV-2 recovered as compared to naïve vaccinees following BNT162b2 and ChAdOx1 nCoV-19, respectively (all p<0.001). Figure 3 A-C and Table S1. **Discussion** Using a large cohort with longitudinally collected blood samples following SARS-COV-2 vaccination, we show that vaccination following SARS-COV-2 infection resulted in remarkably and sustained higher antibody titres with an increased neutralizing potency and breadth against SARS-CoV-2 variants as compared to vaccination in SARS-COV-2 naïve individuals. Furthermore, we reveal a significant decline in BAU/ml and pseudo-neutralizing antibody titres over the first months following both ChAdOx1 nCoV-19 and BNT162b2 vaccination. Direct comparisons showed substantially lower titres following immunization with ChAdOx1 nCoV-19 compared to BNT162b2. These findings are important for decisions on booster doses and design of current and future SARS-CoV-2 vaccine programs, as these should be

271

272273

274

275276

277

278

279

280

281

282283

284

285

286

287

288

289

290

291

292293

294

295

296

297

298299

300

301 302

303

based on data from effectiveness studies and serological investigations calibrated against WHO standards. We and others have previously shown that COVID-19 convalescents mount strong immune responses following mRNA  $^{9,19-23}$  and adenovirus-vectored vaccines  $^{24}$ . We here extend these findings by showing that antibody titres remain substantially increased over three months following ChAdOx1 nCoV-19, and seven months following BNT162b2 in SARS-CoV-2 infected HCW with mild disease prior to vaccination. This suggests that the immune-strengthening effect of exposure to infection followed by vaccination is not a temporary phenomenon. It was recently demonstrated that the memory compartment continues to evolve after both natural infection and vaccination, but with a lesser increase in breadth following vaccination as compared to infection <sup>18</sup>. Importantly, we found that SARS-CoV-2 recovered vaccinees developed antibodies capable of neutralizing SARS-CoV-2 variants to a higher extent than SARS-CoV-2 naive vaccinees. Neutralizing capacity against ten SARS-CoV-2 variants analysed, including all four VOCs, remained substantially higher in SARS-CoV-2 recovered vaccinees as compared to SARS-CoV-2 naive vaccinees throughout the study period. Although vaccinated SARS-CoV-2 recovered individuals may eventually need a booster, these findings suggest that vaccine in immune competent SARS-CoV-2 recovered evokes antibody levels that are sufficient for protection during a longer time period than those rendered in SARS-CoV-2 naïve vaccinees. Our findings of substantial reductions in antibody titres over the first three months following ChAdOx1 nCoV-19 and seven months following BNT162b2 are in line with several reports of waning vaccine efficacy from countries including Israel 4,5, UK 6,7 and the US 8. The comparatively lower titres following ChAdOx1 nCoV-19 are also in line with prior data on lower vaccine efficacy of adenovirus vector-based vaccines as compared to mRNA vaccines <sup>2,32</sup>. Specific antibody levels are used as a correlate of protection against infection following several established vaccines <sup>33</sup>, and for SARS-CoV-2, binding and pseudo-neutralizing antibody titres correlate inversely with risk of infection <sup>14,34</sup>. Extensive efforts are therefore now invested into establishing the levels at which vaccine-generated antibodies protect against infection, aiming to facilitate rapid licensure of new vaccine platforms, support recommendations for vaccine

305

306 307

308309

310

311

312

313

314315316

317318

319

320

321

322

323324

325

326

327328

329

330

331

332333

334

335

336

337

boosters and inform public health decisions. One such effort recently presented an 80% vaccine efficacy against symptomatic SARS-COV-2 infection at 264 BAU/ml, declining to 60% vaccine efficacy at 54 BAU/ml <sup>35</sup>. These estimates were derived from a cohort vaccinated with the ChAdOx1 nCoV-19 vaccine, but similar levels are shown for mRNA vaccines <sup>36</sup>. Although these correlates require validation in further cohorts, our findings show that antibody titres have declined below these thresholds in a portion of study participants within 3-7 months from the second vaccine dose. Importantly, the estimations were derived in eras with a dominance of the Alpha variant, and the estimated titres may provide lower efficacy against infection with the current globally spreading Delta variant <sup>37-39</sup>, which seems to have a higher transmissibility 40,41. Optimal dose interval has been proposed to convey better vaccine efficacy via improved memory formation <sup>17</sup>. A longer interval may indeed generate an improved memory formation, albeit at the price of a suboptimal protection during the longer interval between first and second dose in SARS-CoV-2 naïve populations. Although no significant differences in binding antibody titres, a slight elevation in pseudoneutralization titres were found between the 3-4 week and 6-8 week dose interval in SARS-CoV-2 naïve participants, could indicate improved memory formation in the latter 42. Continued studies are needed to address potential differences in longevity of the immunological memory induced by different prime boost intervals and combinations of various vaccine platforms, as well as the optimal timing of additional vaccine doses. This study is limited by the observational and single-centre nature. The study cohort moreover comprised HCW, and a majority of women of general working age. Antibody trajectories may differ in older populations, and in settings without repeated viral encounters with potential boosting of the immune memory. In summary, our findings of a considerable antibody decline over 3-7 months, paralleled with reports of waning vaccine effectiveness within the same time frame, supports the administration of a third vaccine dose, particularly in individuals with risk factors for severe COVID-19. However, the striking and sustained increased titres and neutralizing breadth of antibodies in previously SARS-CoV-2 infected vaccinees

338 as compared to SARS-CoV-2 naive vaccinees highlights the strong impact of

infection prior to vaccination. These findings suggest that prior infection should be

taken into consideration when planning booster doses and design of current and

future SARS-CoV-2 vaccine programs.

### **Declaration of Interests**

339

340

342343344

347348

356357

360361362

- 345 SoH has participated on AstraZeneca COVID-19 SCG Virtual Advisory Board.
- Otherwise, the authors declare no competing interests.

## Acknowledgements

- 349 This work was funded by Jonas & Christina af Jochnick foundation; Lundblad family
- foundation; Region Stockholm; Knut and Alice Wallenberg foundation; Science for
- Life Laboratory (SciLifeLab); Erling-Persson family foundation; CIMED and the
- 352 Swedish Research Council. The funders above had no role in the design and
- conduct of the study; collection, management, analysis, and interpretation of the
- data; preparation, review, or approval of the manuscript; and decision to submit the
- 355 manuscript for publication.

#### Data sharing

- The anonymized datasets generated during and/or analysed during the current study
- are available from the corresponding author on reasonable request.

### References

- 363 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
- Covid-19 Vaccine. New England Journal of Medicine 2020;383:2603-15.
- 2. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1
- 366 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
- controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.
- 368 3. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2
- mRNA Covid-19 Vaccine through 6 Months. N Engl J Med 2021.
- 370 4. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity of the BNT162b2
- 371 vaccine: A nationwide study from Israel. medRxiv 2021:2021.08.24.21262423.

- 372 5. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster
- against Covid-19 in Israel. N Engl J Med 2021;385:1393-400.
- 6. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and
- vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv
- 376 2021:2021.08.18.21262237.
- 377 7. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second
- dose of BNT162b2 or ChAdOx1. Lancet 2021;398:385-7.
- 379 8. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-
- 380 19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective
- 381 cohort study. The Lancet.
- 382 9. Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell
- responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci
- 384 Immunol 2021;6.
- Mazzoni A, Di Lauria N, Maggi L, et al. First-dose mRNA vaccination is sufficient to
- reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from
- 387 COVID-19. J Clin Invest 2021;131.
- 388 11. Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4(+)
- 389 T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA
- 390 vaccination. Immunity 2021;54:2133-42.e3.
- 391 12. Oberhardt V, Luxenburger H, Kemming J, et al. Rapid and stable mobilization of
- 392 CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature 2021;597:268-73.
- 393 13. Havervall S, Ng H, Falk AJ, et al. Robust humoral and cellular immune responses and
- low risk for reinfection at least eight months following asymptomatic to mild COVID-19. J
- 395 Intern Med 2021.
- 396 14. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
- 397 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med
- 398 2021;27:1205-11.
- 399 15. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in
- 400 Vaccinated Health Care Workers. N Engl J Med 2021.
- 401 16. Kristiansen PA, Page M, Bernasconi V, et al. WHO International Standard for anti-
- 402 SARS-CoV-2 immunoglobulin. Lancet (London, England) 2021;397:1347-8.
- 403 17. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back.
- 404 Immunity 2010;33:451-63.

- 405 18. Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor binding
- domain antibody evolution after mRNA vaccination. Nature 2021.
- 407 19. Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive
- 408 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 2021;384:1372-
- 409 4.
- 410 20. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant
- 411 neutralizing antibodies elicited by SARS-CoV-2 infection. Science 2021.
- 412 21. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-
- 413 CoV-2 and circulating variants. Nature 2021;592:616-22.
- 414 22. Lucas C, Vogels CBF, Yildirim I, et al. Impact of circulating SARS-CoV-2 variants
- on mRNA vaccine-induced immunity. Nature 2021.
- 416 23. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2
- 417 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 2021;27:981-
- 418 4.
- 419 24. Havervall S, Marking U, Greilert-Norin N, et al. Antibody responses after a single
- dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-
- 421 CoV-2. EBioMedicine 2021;70:103523.
- 422 25. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S.
- 423 Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. New England Journal
- 424 of Medicine 2021;384:2092-101.
- 425 26. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large
- 426 Health Care Organization. New England Journal of Medicine 2021.
- 427 27. Rudberg AS, Havervall S, Manberg A, et al. SARS-CoV-2 exposure, symptoms and
- seroprevalence in healthcare workers in Sweden. Nat Commun 2020;11:5064.
- 429 28. Havervall S, Rosell A, Phillipson M, et al. Symptoms and Functional Impairment
- 430 Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA 2021.
- 431 29. Hober S, Hellström C, Olofsson J, et al. Systematic evaluation of SARS-CoV-2
- antigens enables a highly specific and sensitive multiplex serological COVID-19 assay. Clin
- 433 Transl Immunology 2021;10:e1312.
- 434 30. Varnaite R, Garcia M, Glans H, et al. Expansion of SARS-CoV-2-Specific Antibody-
- 435 Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19
- 436 Patients. J Immunol 2020;205:2437-46.
- 437 31. Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination
- enhances peak antibody generation in older people. medRxiv 2021:2021.05.15.21257017.

- 439 32. Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in Antibodies to SARS-
- 440 CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. JAMA 2020.
- 441 33. Plotkin SA. Correlates of protection induced by vaccination. Clinical and vaccine
- 442 immunology: CVI 2010;17:1055-65.
- 443 34. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a
- protective correlate for COVID-19 vaccines. Vaccine 2021;39:4423-8.
- 445 35. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
- asymptomatic SARS-CoV-2 infection. Nature medicine 2021.
- 447 36. Gilbert PB, Montefiori DC, McDermott A, et al. Immune Correlates Analysis of the
- 448 mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv 2021:2021.08.09.21261290.
- 449 37. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in
- 450 Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet
- 451 2021;397:2461-2.
- 452 38. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines
- against the B.1.617.2 (Delta) Variant. New England Journal of Medicine 2021.
- 454 39. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2
- 455 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 2021;397:2331-3.
- 456 40. Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-
- 457 2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta),
- 458 and B.1.617.2 (Delta). Clin Infect Dis 2021.
- 459 41. Teyssou E, Delagrèverie H, Visseaux B, et al. The Delta SARS-CoV-2 variant has a
- higher viral load than the Beta and the historical variants in nasopharyngeal samples from
- newly diagnosed COVID-19 patients. J Infect 2021;83:e1-e3.
- 462 42. Pettini E, Pastore G, Fiorino F, Medaglini D, Ciabattini A. Short or Long Interval
- between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity? Vaccines
- 464 2021;9:289.

# 473 Tables

	SARS-CoV-2 naïve			SARS-CoV-2 recovered		
	N	Age (IQR)	Female (%)	N	Age (IQR)	Female (%)
BNT162b2 (3-4 weeks d.	i.)					
Total	262			75		
6 weeks p.v. (5-8)	69	50 (40-56)	84	27	50 (41-55)	81
12 weeks p.v. (11-14)	175	51 (40-57)	90	52	48 (39-56)	81
29 weeks p.v. (27-30)	246	50 (40-57)	87	68	49 (39-57)	82
BNT162b2 (6-8 weeks d.	i.)					
Total	36			36		
12 weeks p.v. (11-14)	36	61 (54-62)	92	36	54 (40-60)	86
ChAdOx1 nCoV-19 (10-1	2 weeks o	d.i.)				
Total	61			47		
3 weeks p.v. (2-3)	48	52 (42-57)	90	35	52 (44-58)	86
14 weeks p.v. (13-15)	56	51 (38-56)	89	44	52 (44-57)	86

**Table 1. Demographics of study participants**. Age is presented as median with IQR; inter-quartile range. Weeks post second vaccine dose refers to point in time where sampling occurred and are presented as median together with the range. d.i.; dose interval, p.v.; post second vaccine dose.

	SA	SARS-CoV-2 naïve		SARS-CoV-2 recovered		
	GMTs	95% CI	GMTs	95% CI		
SARS-CoV-2 wild type IgG (BA	U/ml)					
BNT162b2 (3-4 weeks d.i.)						
6 weeks p.v. (5-8)	981	(853-1128)	1875	(1222-2878)		
12 weeks p.v. (11-14)	470	(430-513)	1278	(911-1793)		
29 weeks p.v. (27-30)	148	(135-162)	524	(396-694)		
BNT162b2 (6-8 weeks d.i.)						
12 weeks p.v. (11-14)	535	(414-692)	1345	(1043-1735)		
ChAdOx1 nCoV-19 (10-12 weeks	s d.i.)					
3 weeks p.v. (2-3)	195	(137-275)	1350	(954-1910)		
14 weeks p.v. (13-15)	105	(86-129)	591	(438-798)		
Pseudo-neutralizing Ab (wild ty	ype variant) (AU	/ml)				
BNT162b2 (3-4 weeks d.i.)	15 5	(10 F 17 7)	62.2	(22.0.117.2)		
6 weeks p.v. (5-8)	15.5	(13.5-17.7)	62.2	(33.0-117.2)		
12 weeks p.v. (11-14)	8.5	(7.6-9.5)	27.2	(18.2-40.8)		
29 weeks p.v. (27-30)	4.7	(4.5-5.0)	12.1	(9.7-15.2)		
BNT162b2 (6-8 weeks d.i.)	10.0	(0.0.40.0)	00.0	(00.7.44.0)		
12 weeks p.v. (11-14)	10.9	(8.6-13.8)	30.2	(20.7-44.0)		
ChAdOx1 nCoV-19 (10-12 weeks	•	(5.4.0.0)	40.7	(44.0.00.4)		
3 weeks p.v. (2-3)	5.7	(5.1-6.3)	16.7	(11.9-23.4)		
14 weeks p.v. (13-15)	4.0	(3.6-4.5)	12.7	(9.5-16.9)		
Pseudo-neutralizing Ab (Delta BNT162b2 (3-4 weeks d.i.)	variant) (AU/ml)					
6 weeks p.v. (5-8)	21.9	(18.1-26.5)	62.6	(30.8-127.0)		
12 weeks p.v. (11-14)	8.4	(7.1-9.9)	30.1	(20.4-44.5)		
29 weeks p.v. (27-30)	4.8	(4.0-5.7)	17.5	(13.7-22.2)		
BNT162b2 (6-8 weeks d.i.)	1.0	(1.0 0.1)	17.0	(10.1 22.2)		
12 weeks p.v. (11-14)	14.6	(11.5-18.5)	40.1	(29.2-55.2)		
ChAdOx1 nCoV-19 (10-12 weeks	_	(		(_0.2 00.2)		
3 weeks p.v. (2-3)	8.0	(7.1-9.0)	24.2	(18.4-31.7)		
14 weeks p.v. (13-15)	2.7	(1.6-4.3)	16.1	(10.9-23.6)		

Table 2. Geometric mean titers (GMTs) of SARS-CoV-2 wild type spike IgG and pseudo-neutralizing antibodies in the different study groups. Weeks post second vaccine dose refers to point in time where sampling occurred and are presented as median together with the range. CI; confidence interval, Ab; antibodies, d.i.; dose interval, p.v.; post second vaccine dose, AU; arbitrary unit, BAU; binding antibody unit.

## **Figures**





Figure 1. Timeline for vaccination and sample collection. The cohort is divided into participants receiving BNT162b2 with a 3-4 week and a 6–8 week dose interval and ChAdOx1 nCoV-19 with a 10-12 week dose interval. Blue characters represent vaccinees that received BNT162b2 and yellow characters represent vaccinees that received ChAdOx1 nCoV-19. Light colored characters represent SARS-CoV-2 naïve and dark colored characters represent participants with SARS-CoV-2 infection prior vaccination. Test tubes represent time for blood sampling and syringes represent time for vaccination. w; weeks. d.i.; dose interval.









Figure 2. Binding and pseudo-neutralizing antibody titers over time following BNT162b2 and ChAdOx1 nCoV-19 vaccination with and without prior SARS-CoV-2 infection. A) Binding antibody titers against SARS-CoV-2 wild type over 7 months following the second BNT162b2 dose and 3 months following the second ChAdOx1 nCoV-19 dose in SARS-CoV-2 recovered and naïve vaccinees, B) pseudo-neutralizing antibodies against the wild type over 7 months following the second BNT162b2 dose and 3 months following the second ChAdOx1 nCoV-19 dose in SARS-CoV-2 recovered and naïve vaccinees, and C) pseudo-neutralizing

antibodies against the Delta variant type over 7 months following the second BNT162b2 dose and 3 months following the second ChAdOx1 nCoV-19 dose in SARS-CoV-2 recovered and naïve vaccinees. Dots and crosses represent geometric mean titers and bars represent 95 % CI. Solid lines represent SARS-CoV-2 recovered vaccinees and dotted lines represent SARS-CoV-2 naïve vaccinees. WT; wild type, BAU; binding antibody units, AU; arbitrary units.







535

536

Figure 3. Neutralizing capacity over time. Neutralizing capacity A) 3 months and B) 7 months post BNT162b2 vaccination and C) 3 months post ChAdOx1 nCoV-19 vaccination against ten SARS-CoV-2 variants including the wild type (WT), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.526.1 (New York), B.1.617 (India), B.1.617.1 (Kappa),

- 538 B.1.617.2 (Delta), B.1.617.3 (India), P.1 (Gamma), and P.2 (Zeta) variants. Dots
- represent geometric mean titers and bars represent 95 % CI. Dark colored dots
- 540 represent SARS-CoV-2 recovered vaccinees and light colored dots represent SARS-
- 541 CoV-2 naïve vaccinees.